Dipyridamole in the treatment of dengue haemorrhagic fever

Area of Science:

• Pediatrics
• Pharmacology
• Infectious Diseases

Background:

• Dengue Hemorrhagic Fever (DHF) is a severe mosquito-borne viral illness.
• Standard DHF treatment involves fluid and electrolyte management, with blood products and plasma expanders as needed.
• Heparin is used for disseminated intravascular coagulation (DIC) in severe DHF cases.

Purpose of the Study:

• To evaluate the efficacy of dipyridamole and aspirin (ASA) as adjuvant therapy for DHF in children.
• To assess the impact of dipyridamole and ASA on DHF mortality and disease severity progression.

Main Methods:

• A clinical study involving 54 children diagnosed with DHF.
• Dipyridamole and ASA were administered as an adjunct to standard DHF treatment.
• Standard therapy included fluids, electrolytes, blood, plasma, and plasma expanders.
• Heparin was administered to patients with DIC.

Main Results:

• Dipyridamole and ASA did not significantly reduce the overall mortality rate in DHF patients.
• The combination therapy showed a significant effect in preventing the progression of DHF severity.
• Disease progression from Grade I and II to Grade III and IV was inhibited by dipyridamole and ASA.

Conclusions:

• Dipyridamole and ASA may be beneficial in managing DHF by preventing disease severity escalation.
• Further research is warranted to confirm these findings and explore optimal DHF treatment strategies.